trending Market Intelligence /marketintelligence/en/news-insights/trending/GfoxMDJr2WLLtLs130FByQ2 content esgSubNav
In This List

Biogen secures US FDA approval for spinal muscular atrophy treatment

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


Biogen secures US FDA approval for spinal muscular atrophy treatment

Biogen Inc. said it received U.S. FDA approval for SPINRAZA, a treatment for spinal muscular atrophy.

The drug was approved following positive results from multiple clinical studies in more than 170 patients. In a controlled clinical study, those treated with the drug showed clinically meaningful improvements in their motor functions. Also, a greater percentage of patients on the drug survived compared to untreated patients.

Biogen plans to make the drug available for shipment in the U.S. to healthcare providers in about a week.